Based on ratings from 0 stock analysts, the Cardio Diagnostics Holdings Inc. stock price is expected to increase by 545.16% in 12 months. This is calculated by using the average 12-month stock price forecast for Cardio Diagnostics Holdings Inc.. The lowest target is $2 and the highest is $2. Please note analyst price targets are not guaranteed and could be missed completely.
CDIO is a stock in Health Care which has been forecasted to be worth $2 as an average. On the higher end, the forecast price is $2 USD by Bruce Jackson from Benchmark and on the lower end CDIO is forecasted to be $2 by Bruce Jackson from Benchmark.
These are the latest 20 analyst ratings of CDIO.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Bruce Jackson Benchmark | Speculative Buy | $2 | Reiterates | Aug 27, 2024 |
Bruce Jackson Benchmark | Speculative Buy | $2 | Maintains | Jun 6, 2024 |
Bruce Jackson Benchmark | Speculative Buy | $1.35 | Maintains | Apr 19, 2024 |
Bruce Jackson Benchmark | Speculative Buy | $8 | Reiterates | Jun 15, 2023 |
Carl Byrnes Northland Capital Markets | Outperform | $8 | Initiates | May 22, 2023 |
Bruce Jackson Benchmark | Speculative Buy | $8 | Reiterates | Apr 18, 2023 |
When did it IPO
2022
Staff Count
7
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Meeshanthini V. Dogan Ph.D.
Market Cap
$9.5M
In 2023, CDIO generated $17,065 in revenue, which was a increase of 1,696.32% from the previous year. This can be seen as a signal that CDIO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - CHICAGO--(BUSINESS WIRE)--CDIO.AI emphasizes Cardio Diagnostics' AI-first, scalable solutions for preventing, detecting and managing cardiovascular disease.
Summary - CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum.
Summary - CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood test, Epi+Gen CHD is now available at FMS' retail clinical location at the Meijer Supercenter in McHenry, IL.
Summary - CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit.
Summary - CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the MolDx program.
Summary - CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood tests are now available at FMS' newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois.